TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20681275
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (anti-platelet, blood lipid regulating, anti-ischemia) without SXBXP.
Study: 20681275
Drug: Shexiang Baoxin
Normalized name: CAMPHOR (NATURAL) 30.53 mg / MENTHOL 40.71 mg / METHYL SALICYLATE 25.95 mg TOPICAL PLASTER [SheXiang ZhuangGu Gao]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shexiang Baoxin Pill (SXBXP)
Study: 12455714
Drug: Angiotensin converting
Normalized name: Angiotensin converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin converting enzyme inhibitors (ACEI) for four weeks
Study: 8530573
Drug: leuprolide depot
Normalized name: leuprolide acetate Injectable Suspension [Lupron Depot]
Approvals — FDA: no, EMA: no, PMDA: no
Description: leuprolide depot (3.75 mg/month) plus conjugated estrogen (0.625 mg/day) and medroxyprogesterone acetate (10 mg; days 1‐12)
Study: 8530573
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive pills (OCP) containing ethynodiol diacetate (1 mg) and ethinyl estradiol (35 micrograms)
Study: 30037514
Drug: 30 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL/kg of intravenous Lactated Ringer's solution (LR)
Study: 26690555
Drug: Acetaminophen (APAP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (APAP; 1 g every 6 hours for seven days)
Study: 24612987
Drug: Trimethoprim-sulfamethoxazole (160/800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (160/800 mg daily)
Study: 22065252
Drug: Modular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modular treatment (62 youths)
Study: 22065252
Drug: Standard manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard manual treatment (59 youths)
Study: 16217327
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin B (5,000 IU diluted up to 20 ml)
Study: 8018617
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 ml normal saline)
Study: 11948071
Drug: Placebo-controlled study
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-controlled study for treatment of asthma
Study: 9585802
Drug: Eprosartan 350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan 350 mg
Study: 9585802
Drug: Eprosartan 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan 10 mg
Study: 9585802
Drug: Eprosartan 30
Normalized name: eprosartan 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan 30 mg
Study: 9585802
Drug: Eprosartan 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan 50 mg
Study: 9585802
Drug: Eprosartan 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan 70 mg
Study: 9597557
Drug: Eprosartan 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan 100 mg
Study: 9597557
Drug: Eprosartan 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan 200 mg
Study: 7857995
Drug: Active experimental
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active experimental drug
Study: 31941795
Drug: N-acetylcysteine (NAC),
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC), 2,700 mg/d for adults; 30 mg/kg/d for pediatrics
Study: 28662618
Drug: Face-to-face treatments
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face treatments (16 studies)
Study: 28662618
Drug: Self-guided treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-guided treatments (11 studies)
Study: 21645184
Drug: Rivastigmine patch
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine patch (9.5 mg/24 h)
Study: 21312297
Drug: Rivastigmine capsules
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine capsules (12 mg/day)
Study: 19334486
Drug: ronkoleukine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ronkoleukine therapy (0.1 mg submucously and 0.4 mg intravenously, 3 times with 72 hour intervals)
Study: 19334486
Drug: standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard therapy (proton pump inhibitor and two antibiotics: amoxicillin and clarithromycin)
Study: 16686568
Drug: Mock Treatment
Normalized name: smocks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mock Treatment (MT; 29.50 degrees C)
Study: 10357114
Drug: Sodium aurothiomalate
Normalized name: Sodium aurothiomalate
DrugBank: Sodium aurothiomalate (DB09276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium aurothiomalate (gold therapy)
Study: 7594922
Drug: Multidrug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidrug therapy regimen including rifampin, isoniazid, clofazimine, and dapsone for the first 3 months followed by clofazimine and dapsone until 84 months.
Study: 7395586
Drug: Assertiveness training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assertiveness training (twice a week for one hour for 10 weeks)
Study: 30604381
Drug: GM1 acupoint
Normalized name: Ganglioside GM1
DrugBank: Ganglioside GM1 (DB16948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM1 acupoint injection (group A)
Study: 30604381
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection (group B)
Study: 27998971
Drug: S-288310 at
Normalized name: crospovidone (15 mpa.s at 5%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-288310 at 1 mg
Study: 27998971
Drug: S-288310 at
Normalized name: crospovidone (15 mpa.s at 5%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-288310 at 2 mg
Study: 25090414
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG), 10% Purified (Gamunex) administered monthly.
Study: 25090414
Drug: 0.1% albumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% albumin solution (placebo) administered monthly.
Study: 17240130
Drug: Wormwood (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wormwood (3 x 500 mg/day)
Study: 15665022
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg three times daily for 6 months
Study: 9658743
Drug: Oral zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zinc tolerance test
Study: 9658743
Drug: Oral zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zinc dipicolinate tolerance test
Study: 30898388
Drug: Intravenous Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Acetaminophen (IA) 1000 mg every 6 hours
Study: 30898388
Drug: Intravenous Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Acetaminophen (IA)
Study: 29145879
Drug: 2×10^6 per
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2×10^6 per kilogram human umbilical-cord-derived MSCs (UC-MSCs) via peripheral vein injection preoperatively, and 5×10^6 cells via renal arterial injection during surgery, with standard induction therapy
Study: 21518701
Drug: Leuprorelin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprorelin therapy
Study: 20035579
Drug: Risperidone 1-3
Normalized name: risperidone 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 1-3 mg/day
Study: 21299844
Drug: Risperidone 4-6
Normalized name: risperidone 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 4-6 mg/day
Study: 15361496
Drug: Slow ramp
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow ramp rectal distension (40 ml/min)
Study: 15361496
Drug: Rapid phasic
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid phasic rectal distension (900 ml/min, 10, 20, 30, and 40 mm Hg)
Study: 9725691
Drug: Vancomycin administration
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin administration during surgery
Study: 26067628
Drug: Ultrasound-guided pulsed
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided pulsed radiofrequency (PRF) treatment and night splint
Study: 7582395
Drug: Inhaled B-agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled B-agonist
Study: 2350094
Drug: Codeine (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine (90 mg)
Study: 31673875
Drug: Fluconazole 400
Normalized name: fluconazole 400 MG in 200 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 400 mg/day orally on days 1-11, single oral dose of erdafitinib 4 mg on day 5
Study: 31673875
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg/day orally on days 1-11, single oral dose of erdafitinib 4 mg on day 5
Study: 31673875
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of erdafitinib 4 mg
Study: 27437826
Drug: PC-1005 (MIV-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: PC-1005 (MIV-150 and zinc acetate in a carrageenan gel)
Study: 22418831
Drug: Itraconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (200 mg daily for 5 days)
Study: 15968009
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) - 0.625 mg of conjugated estrogen daily, plus 5 mg of medroxyprogesterone for 12 days per month
Study: 1283553
Drug: Deeper somatic
Normalized name: Bos taurus somatic nerve preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deeper somatic pain descriptors (e.g., throbbing, stabbing, cramping, pulling, burning)
Study: 1283553
Drug: Superficial pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superficial pain descriptors (e.g., pricking, sharp, pinching, itching, sore, tender)
Study: 24117531
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg (single dose)
Study: 24117531
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg (multiple doses)
Study: 15958837
Drug: Indinavir/Ritonavir 800/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir/Ritonavir 800/200 mg twice daily
Study: 15958837
Drug: Indinavir/Ritonavir 400/400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir/Ritonavir 400/400 mg twice daily
Study: 11796432
Drug: Tobramycin solution
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin solution for inhalation (TSI) 300 mg
Study: 10232690
Drug: big ET‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: big ET‐1 infusion (0.2, 1, and 4 pmol/kg per min for 20 min)
Study: 10232690
Drug: big ET‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: big ET‐1 infusion
Study: 10232690
Drug: ET‐1 infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: ET‐1 infusion
Study: 1297921
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (any treatment for hyperbilirubinemia)
Study: 29389245
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g daily ARA for 4 weeks
Study: 6124495
Drug: Standard conservative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard conservative therapy
Study: 19704275
Drug: Brace therapy
Normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brace therapy for compression fractures
Study: 19704275
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy and postural instructions for compression fractures
Study: 16926249
Drug: Pegvisomant (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegvisomant (doses 10-60 mg)
Study: 11385196
Drug: Fluoride group
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride group (mothers received fluoride varnish treatments at 6, 12, and 18 months after delivery)
Study: 11385196
Drug: Chlorhexidine group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine group (mothers received chlorhexidine varnish treatments at 6, 12, and 18 months after delivery)
Study: 8506477
Drug: Ofloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (400 mg twice daily for 10 days)
Study: 8506477
Drug: Cefoxitin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (2 g intramuscularly) followed by doxycycline (100 mg twice daily orally for 10 days)
Study: 3899677
Drug: Vinpocetine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinpocetine 40 mg
Study: 27523947
Drug: Milbemycin oxime/praziquantel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milbemycin oxime/praziquantel tablets (G3)
Study: 24871654
Drug: High-dose Ginseol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Ginseol K‐g1 (300 mg)
Study: 24871654
Drug: Low-dose Ginseol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Ginseol K‐g1 (100 mg)
Study: 21186645
Drug: Cycloferon liniment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycloferon liniment in combined therapy
Study: 18794178
Drug: Etanercept plus
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept plus sulfasalazine (2-3 g/day)
Study: 15786440
Drug: Jet nebulizer
Normalized name: Pari LC Jet Nebulizer Plus RE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jet nebulizer (0.15 mg/kg salbutamol respiratory solution)
Study: 11976156
Drug: High-fiber diet
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fiber diet (4 servings/d of foods containing beta-glucan or psyllium delivering 8 g/d more soluble fiber)
Study: 3261614
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (15 women)
Study: 11318787
Drug: Acipimox (A)
Normalized name: acipimox
DrugBank: Acipimox (DB09055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (A) 250 mg, orally, administered at -210 minutes and -60 minutes
Study: 27379793
Drug: High carbohydrate
Normalized name: High carbohydrate food
Approvals — FDA: no, EMA: no, PMDA: no
Description: High carbohydrate diet (8 g kg(‐1))
Study: 27379793
Drug: Low carbohydrate
Normalized name: Low carbohydrate beer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low carbohydrate diet (3 g kg(‐1))
Study: 19713256
Drug: DEX (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX (both doses)
Study: 18631245
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg azithromycin once a day for 3 days
Study: 12022709
Drug: Alfuzosin 10
Normalized name: Alfuzosin 10mg Oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin 10 mg o.d.
Study: 30219823
Drug: Low-dose methotrexate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methotrexate (LDMTX)
Study: 3481039
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (HDMTX)
Study: 9454116
Drug: Crystallization test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystallization test with cupric chloride solution in patients with head and neck neoplasms
Study: 343256
Drug: Cefazolin and
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin and cephalexin (prophylactic antibiotics)
Study: 24756462
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of ibandronic acid (T)
Study: 24756462
Drug: Bonviva(®) (R)
Normalized name: Boniva
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bonviva(®) (R) - first dosing
Study: 24756462
Drug: Bonviva(®) (R)
Normalized name: Boniva
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bonviva(®) (R) - second dosing
Study: 17625432
Drug: Amantadine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine (200 mg/day, orally)
Study: 9552780
Drug: Propofol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (3 mg/kg/h)
Study: 3421279
Drug: Antenatal vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal vitamin K1 (10 mg intramuscularly every 5 days until delivery)
Study: 3421279
Drug: No antenatal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antenatal vitamin K1 therapy
Study: 25855751
Drug: Pay-for-reporting intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pay-for-reporting intervention with monthly incentive fees and chart audits every 6 months.
Study: 16537663
Drug: Fondaparinux (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux (2.5 mg daily)
Study: 16537663
Drug: Enoxaparin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (1 mg per kilogram of body weight twice daily)
Study: 8129540
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg + Nifedipine 20 mg (AN)
Study: 3524837
Drug: Carmustine (BCNU)
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carmustine (BCNU) at total doses less than 902 mg/m2
Study: 3524837
Drug: Carmustine (BCNU)
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carmustine (BCNU) at total doses greater than 902 mg/m2
Study: 3524837
Drug: Carmustine (BCNU)
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carmustine (BCNU) at total doses exceeding 1400 mg/m2
Study: 3524837
Drug: Misonidazole administration
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misonidazole administration
Study: 22316106
Drug: Allopurinol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (200 mg or 300 mg depending on renal function)
Study: 20649528
Drug: High volume/low
Approvals — FDA: no, EMA: no, PMDA: no
Description: High volume/low concentration solution of ropivacaine (20 ml, 0.5%)
Study: 20649528
Drug: Low volume/high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low volume/high concentration solution of ropivacaine (10 ml, 1%)
Study: 20649528
Drug: Ropivacaine injection
Normalized name: ROPivacaine Injection
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine injection
Study: 15991756
Drug: Pharmacist-guided education
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-guided education and monitoring (PGEM) through three monthly telephone calls
Study: 1777051
Drug: Theophylline L.A.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline L.A.
Study: 6362597
Drug: Immune globulin
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune globulin (0.06 mL/kg of body weight)
Study: 6362597
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B immune globulin (0.06 mL/kg of body weight)
Study: 6362597
Drug: Immune globulin
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune globulin (twice the dose of the first group)
Study: 28460586
Drug: [6S]-5-methyltetrahydrofolate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: [6S]-5-methyltetrahydrofolate (400 μg/d)
Study: 28460586
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (400 μg/d)
Study: 28634649
Drug: Cabozantinib (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib (140 mg/day)
Study: 22849308
Drug: 10 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL/kg IV fluid administration
Study: 22849308
Drug: 30 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL/kg IV fluid administration
Study: 22849308
Drug: 2 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL/kg IV fluid administration (control group)
Study: 20705558
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy plus zoledronic acid
Study: 18502360
Drug: 0.0 mg
Normalized name: RUXOLITINIB 10.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0 mg intrathecal morphine (Control)
Study: 10195531
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg intrathecal morphine
Study: 18502360
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg intrathecal morphine
Study: 18502360
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg intrathecal morphine
Study: 18502360
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (0.1 to 0.4 mg)
Study: 21824444
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg HCA
Study: 11443511
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg HCA and 3 g MCT
Study: 11443511
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (PLA, HCA, HCA+MCT)
Study: 9778328
Drug: GnRHa +
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRHa + estrogen/progestogen add-back therapy
Study: 7820145
Drug: rHuEPO by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO by subcutaneous route, initial doses of 20U/kg/dialysis, mean correction dose of 65U/kg/dialysis, maintenance dose of 51U/kg/dialysis
Study: 29949492
Drug: Inhaled glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled glucocorticoid plus LABA (combination therapy)
Study: 29949492
Drug: Inhaled glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled glucocorticoid alone (control)
Study: 25282874
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (MLD and control)